The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia
- 10 July 2013
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 8 (10) , 1297-1307
Abstract
Introduction: Lurasidone is a novel antipsychotic drug approved for the treatment of schizophrenia in adults. It is formulated into tablets, administered orally once/day (dose range 40 – 160 mg/day) does not require titration, but needs to be given with food to maximize its plasma exposure. Areas covered: This review focuses on the preclinical discovery of lurasidone. Furthermore, the article provides analysis on the pharmacological, behavioral and molecular mechanisms of lurasidone and their contribution to its therapeutic advantages. The article is based on the literature reported in published preclinical and clinical studies, product labels, poster presentations and press releases. Expert opinion: Lurasidone demonstrated high affinity for serotonin 5-HT1A, 5-HT2A, 5-HT7, dopamine D2 and adrenergic α2C receptors followed by α1 and α2A receptors. The drug was active in animal models predictive of antipsychotic and antidepressant activities. In addition, it demonstrated procognitive effects, as it was effective in several animal models that assessed memory, cognition and executive functions in rats and in primates. At a cellular level, lurasidone promotes neuronal plasticity, can modulate epigenetic mechanisms controlling gene transcription, and increases the expression of the neurotrophic factor BDNF in cortical and limbic brain regions. Lurasidone's mechanisms of action might contribute to its unique psychopharmacological properties in the improved treatment of schizophrenia, and perhaps other psychiatric disorders.Keywords
This publication has 76 references indexed in Scilit:
- Cortical parvalbumin interneurons and cognitive dysfunction in schizophreniaTrends in Neurosciences, 2012
- Growth Arrest and DNA-Damage-Inducible, Beta (GADD45b)-Mediated DNA Demethylation in Major PsychosisNeuropsychopharmacology, 2011
- Pharmacological Blockade of 5-HT7 Receptors as a Putative Fast Acting Antidepressant StrategyNeuropsychopharmacology, 2011
- Neuroplasticity signaling pathways linked to the pathophysiology of schizophreniaNeuroscience & Biobehavioral Reviews, 2011
- The 5-HT7 receptor as a mediator and modulator of antidepressant-like behaviorBehavioural Brain Research, 2010
- Modeling the Positive Symptoms of Schizophrenia in Genetically Modified Mice: Pharmacology and Methodology AspectsSchizophrenia Bulletin, 2009
- 5-HT1A receptor function in major depressive disorderProgress in Neurobiology, 2009
- Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortexProceedings of the National Academy of Sciences, 2009
- Evaluation of the repeated open-space swim model of depression in the mousePharmacology Biochemistry and Behavior, 2008
- Distinct Role of Long 3′ UTR BDNF mRNA in Spine Morphology and Synaptic Plasticity in Hippocampal NeuronsCell, 2008